Gyre Therapeutics (GYRE) Other Operating Expenses (2012 - 2026)
Gyre Therapeutics (GYRE) reported Other Operating Expenses of $17.9 million for Q1 2026, up 52.67% year-over-year from $11.7 million in Q1 2025, and up 895900.0% on a QoQ basis from -$2000.0 in Q4 2025.
Gyre Therapeutics (GYRE) has 12 years of Other Operating Expenses data on file, last reported at $17.9 million in Q1 2026.
- Quarterly Other Operating Expenses rose 52.67% year-over-year to $17.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.9 million (up 53.5% YoY) and the FY2025 annual result came in at -$4000.0, up 93.94% from the prior year.
- Other Operating Expenses rose to $17.9 million in Q1 2026 per GYRE's latest filing, from -$2000.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $57.2 million in Q2 2022 and bottomed at -$2.2 million in Q4 2023.
- The 5-year median for Other Operating Expenses is $500.0 (2024), against an average of $7.3 million.
- The widest annual swing landed in 2022, when Other Operating Expenses surged 4925.9%; it then slumped 3603.39% in 2023.
- Tracing GYRE's Other Operating Expenses over 5 years: stood at -$59000.0 in 2022, then tumbled by 3603.39% to -$2.2 million in 2023, then jumped by 100.09% to $2000.0 in 2024, then tumbled by 200.0% to -$2000.0 in 2025, then jumped by 895900.0% to $17.9 million in 2026.
- Per Business Quant, the three latest GYRE Other Operating Expenses figures stand at $17.9 million (Q1 2026), -$2000.0 (Q4 2025), and -$1000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.92 Mn |
| Dec 31, 2025 | -2,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Mar 31, 2025 | 11.74 Mn |
| Dec 31, 2024 | 2,000.00 |
| Jun 30, 2024 | -68,000.00 |
| Mar 31, 2024 | 12.54 Mn |
| Dec 31, 2023 | -2.19 Mn |
| Sep 30, 2023 | -526,000.00 |
| Mar 31, 2023 | 4.74 Mn |
| Dec 31, 2022 | -59,000.00 |
| Jun 30, 2022 | 57.25 Mn |
| Mar 31, 2022 | 798,000.00 |
| Dec 31, 2021 | 68.74 Mn |
| Sep 30, 2021 | 2.31 Mn |
| Jun 30, 2021 | 1.14 Mn |
| Mar 31, 2021 | 1.48 Mn |
| Dec 31, 2020 | 46.11 Mn |
| Sep 30, 2020 | 911,000.00 |
| Jun 30, 2020 | 1.74 Mn |
| Mar 31, 2020 | 4.48 Mn |
| Mar 31, 2018 | -116,000.00 |
| Dec 31, 2016 | 1.43 Mn |
| Sep 30, 2016 | 804,000.00 |
| Dec 31, 2015 | 1,000.00 |
| Jun 30, 2015 | -874,000.00 |
| Mar 31, 2015 | -1.16 Mn |
| Dec 31, 2014 | -1,000.00 |
| Jun 30, 2014 | -5.77 Mn |
| Mar 31, 2014 | -9.68 Mn |
| Dec 31, 2012 | 1.41 Mn |